Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration accepted the company’s new drug application for zilganersen and granted it priority review status on March 23, 2026. The FDA’s acceptance sets a Prescription Drug User Fee Act (PDUFA) target action date of September 22, 2026, potentially shortening the review period to six months.
Zilganersen is an antisense oligonucleotide that reduces the production of glial fibrillary acidic protein (GFAP), the protein that accumulates in the brains of patients with Alexander disease. The disease is a rare, progressive neurological disorder with no approved disease‑modifying therapies, making zilganersen the first potential treatment to address the underlying cause.
The priority‑review designation reflects the FDA’s assessment that zilganersen offers a substantial therapeutic advantage in a condition with an unmet medical need. It also signals Ionis’s continued momentum in its commercial transition, following the 2025 launches of TRYNGOLZA and DAWNZERA. Ionis reported Q4 2025 revenue of $203.33 million and a net loss of $229 million, and it has guided 2026 revenue to $800 million–$825 million, underscoring the company’s expectation of accelerated growth as its neurology portfolio matures.
"We are pleased the FDA has granted Priority Review for zilganersen. This decision recognizes the urgent need for treatment options and brings us one step closer to offering patients, who currently have no disease‑modifying therapies, a potential treatment as quickly as possible." – Ionis spokesperson, as quoted by NeurologyLive®
"Alexander disease is a devastating condition, commonly resulting in progressive motor and cognitive dysfunction, loss of independence and is often fatal. There are no approved disease‑modifying treatments, underscoring the significant unmet need in this community." – Brett Monia, PhD, chief executive officer at Ionis
"Priority Review designation underscores the urgent need for treatment options and will enable us to bring zilganersen to patients as quickly as possible." – Brett Monia, PhD, chief executive officer at Ionis
"If approved, zilganersen will be the first and only treatment for Alexander disease, marking a breakthrough for patients who are living with this rare, often fatal neurological condition." – Ionis spokesperson, as quoted by NeurologyLive®
"These data demonstrate the promise of zilganersen to potentially transform the future treatment landscape for this condition and reinforce the power of our technology to address neurological diseases by directly targeting the underlying cause. We are deeply grateful to the patients, families and researchers whose participation has helped make this progress possible." – Brett Monia, PhD, chief executive officer at Ionis
Investors reacted positively to the FDA’s priority‑review decision, citing the regulatory milestone, the substantial unmet need in Alexander disease, and Ionis’s expanding neurology pipeline as key drivers of optimism.
The priority‑review status positions zilganersen for a potentially expedited path to market, offering the first disease‑modifying therapy for Alexander disease and reinforcing Ionis’s strategy to bring a steady cadence of transformational medicines to patients.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.